<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01877252</url>
  </required_header>
  <id_info>
    <org_study_id>CRITISCH132105</org_study_id>
    <nct_id>NCT01877252</nct_id>
  </id_info>
  <brief_title>Registry of First-line Treatments in Patients With Critical Limb Ischemia</brief_title>
  <acronym>CRITISCH</acronym>
  <official_title>National Registry Investigating the Effectiveness of Different First-line Treatment Strategies in Patients With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Franziskus Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Institut für Gefäßmedizinische Gesundheitsforschung gGmbH (DIGG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsche Gesellschaft für Gefäßchirurgie und Gefäßmedizin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Franziskus Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal research question is which treatment modality between open surgical,
      endovascular and conservative therapy is the most effective in terms of limb salvage,
      survival and reinterventions in patients with critical limb ischemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The target population consists of patients suffering from critical limb ischemia (CLI)
      lasting more than 2 weeks. CLI is defined as rest pain or tissue loss (Fontaine stages III-IV
      or Rutherford classes 4 to 6) and/or ankle-brachial index &lt; 0.40. Patient with acute
      limb-threatening ischemia, bone fractures in the relevant areas, nonatherosclerotic disease
      (e.g. arteriitis) and documented hypercoagulable diseases will be excluded from this study.
      There will be no experimental or control groups. The comparison groups will be:

      Group 1: Best endovascular treatment (angioplasty +/- stent) Group 2: Best surgical treatment
      [bypass (vein or prosthetic)] Group 3: Femoral artery patchplasty +/- profundoplasty (+/-
      endovascular treatment) Group 4: Best conservative treatment

      The proposed sample size amounts to 1200 patients.

      To be assessed for eligibility (n=1200) To be allocated to trial (n=1000) To be analysed
      (n=900)

      In CRITISCH registry, randomization or blinding is not feasible, because optimized standard
      care will be performed as established at each participating centre (best medical treatment).
      Data storage, validation, monitoring, update, backup and analysis will be performed centrally
      following established procedures. Web-based software will be used to develop a data model
      representing the data structure. The data validation will include standard data validation
      techniques such as the manual review of selected variables and the routine check of missing
      and outlying data points. Regional staff will be instructed and supervised by study nurse,
      who will perform the study monitoring. Assessment of relevant prognostic factors during the
      statistical analysis will prevent biased results due to the non-randomized design and the
      potential structural inequality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Amputation-free survival</measure>
    <time_frame>at 2 years</time_frame>
    <description>Above-ankle amputation of the index limb or death (any cause), whichever occurred first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative death</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse limb event (MALE)</measure>
    <time_frame>at 1 year, at 2 years</time_frame>
    <description>above ankle amputation of the index limb or major intervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular event (MACCE)</measure>
    <time_frame>at 30 days, at 1 year, at 2 years</time_frame>
    <description>myocardial infarction, stroke or death (any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained clinical improvement</measure>
    <time_frame>at 1 year, at 2 years</time_frame>
    <description>upward shift on the Rutherford or Fontaine classification to a level of intermittent claudication in amputation-free surviving patients without the need for repeated target lesion revascularization (TLR) (primary improvement) or after repeated TLR (secondary improvement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic failure</measure>
    <time_frame>at 30 days, at 1 year, at 2 years</time_frame>
    <description>first occurrence of any of the following events in a time-to-event fashion: (a) major amputation (transtibial or above) and/or (b) reintervention to maintain vascular patency in the index limb and/or (c) failure to increase ankle-brachial-index (ABI) by at least 0.15 postprocedure] and/or (d) decrease in ABI by 0.15</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">1200</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Endovascular treatment</arm_group_label>
    <description>Angioplasty +/- stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open treatment</arm_group_label>
    <description>Bypass (vein or prosthetic)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patchplasty/Hybrid treatment</arm_group_label>
    <description>Femoral artery patchplasty +/- profundoplasty +/- endovascular treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative treatment</arm_group_label>
    <description>no vascular intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical revascularization</intervention_name>
    <arm_group_label>Open treatment</arm_group_label>
    <arm_group_label>Patchplasty/Hybrid treatment</arm_group_label>
    <other_name>Vein</other_name>
    <other_name>PTFE</other_name>
    <other_name>Dacron</other_name>
    <other_name>Femoral artery patchplasty</other_name>
    <other_name>Profunda patchplasty</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular revascularization</intervention_name>
    <arm_group_label>Endovascular treatment</arm_group_label>
    <arm_group_label>Patchplasty/Hybrid treatment</arm_group_label>
    <other_name>Balloon angioplasty</other_name>
    <other_name>Stent</other_name>
    <other_name>Drug-eluting balloon</other_name>
    <other_name>Drug-eluting stent</other_name>
    <other_name>Lysis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No vascular intervention</intervention_name>
    <arm_group_label>Conservative treatment</arm_group_label>
    <other_name>Major amputation</other_name>
    <other_name>Minor amputation</other_name>
    <other_name>Sympatholysis</other_name>
    <other_name>Conservative treatment</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population consists of patients suffering from critical limb ischemia lasting
        more than 2 weeks
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rest pain or tissue loss (Fontaine stages III-IV or Rutherford classes 4 to 6) and/or
             ankle-brachial index &lt; 0.40

        Exclusion Criteria:

          -  Acute limb-threatening ischemia

          -  Bone fractures in the relevant areas

          -  Non-atherosclerotic disease (e.g. arteriitis)

          -  Documented hypercoagulable diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Vascular Surgery, St. Franziskus Hospital</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.digg-dgg.de</url>
    <description>Deutsches Institut für Gefäßmedizinische Gesundheitsforschung (DIGG)</description>
  </link>
  <link>
    <url>http://www.gefaesschirurgie.de</url>
    <description>German Society for Vascular Surgery and Medicine</description>
  </link>
  <reference>
    <citation>Setacci C, de Donato G, Teraa M, Moll FL, Ricco JB, Becker F, Robert-Ebadi H, Cao P, Eckstein HH, De Rango P, Diehm N, Schmidli J, Dick F, Davies AH, Lepäntalo M, Apelqvist J. Chapter IV: Treatment of critical limb ischaemia. Eur J Vasc Endovasc Surg. 2011 Dec;42 Suppl 2:S43-59. doi: 10.1016/S1078-5884(11)60014-2. Review.</citation>
    <PMID>22172473</PMID>
  </reference>
  <reference>
    <citation>Becker F, Robert-Ebadi H, Ricco JB, Setacci C, Cao P, de Donato G, Eckstein HH, De Rango P, Diehm N, Schmidli J, Teraa M, Moll FL, Dick F, Davies AH, Lepäntalo M, Apelqvist J. Chapter I: Definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg. 2011 Dec;42 Suppl 2:S4-12. doi: 10.1016/S1078-5884(11)60009-9. Review.</citation>
    <PMID>22172472</PMID>
  </reference>
  <reference>
    <citation>Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H; BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005 Dec 3;366(9501):1925-34.</citation>
    <PMID>16325694</PMID>
  </reference>
  <reference>
    <citation>Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, Ruckley CV, Raab GM; BASIL trial Participants. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg. 2010 May;51(5 Suppl):5S-17S. doi: 10.1016/j.jvs.2010.01.073. Erratum in: J Vasc Surg. 2010 Dec;52(6):1751. Bhattachary, V [corrected to Bhattacharya, V].</citation>
    <PMID>20435258</PMID>
  </reference>
  <reference>
    <citation>Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL, Nehler MR, Powell RJ, Sidawy AN. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009 Dec;50(6):1462-73.e1-3. doi: 10.1016/j.jvs.2009.09.044. Epub 2009 Nov 7. Review.</citation>
    <PMID>19897335</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2013</study_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Franziskus Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Theodosios Bisdas</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>critical limb ischemia</keyword>
  <keyword>endovascular treatment</keyword>
  <keyword>open surgical repair</keyword>
  <keyword>diabetic foot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

